Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Chinese Patients with GIST
NCT00793871Phase 4Completed
- Sponsor
- Pfizer
- Start
- Nov 2008
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sunitinib in gastrointestinal stromal tumor (GIST), sponsored by Pfizer. Primary endpoint: Progression-free Survival up to 264 weeks. Started Nov 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00793871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00793871.